Developer docs
API playgroundTry for free, no card

Search company profiles

Abeona Therapeutics

Full company profile

uuid0000mys

Namestring
Abeona Therapeutics
Legal namestring
Abeona Therapeutics Inc.
Company typeenum
Public
Founded yearint
2015
Descriptiontext

Abeona Therapeutics Inc. (NASDAQ: ABEO) is a commercial-stage biopharmaceutical company headquartered in Cleveland, Ohio that develops cell and gene therapies for serious rare diseases. Its lead and only commercial product is ZEVASKYN (prademagene zamikeracel), which received FDA approval on April 28, 2025 as the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB), a severe genetic skin disease caused by a defect in the COL7A1 gene. The therapy uses gene-modified cellular sheets applied to chronic wounds and is priced at $6.2 million for two treatment cycles.

ZEVASKYN is manufactured at Abeona's fully integrated cGMP cell and gene therapy facility in Cleveland and administered exclusively through a Qualified Treatment Center network that includes Lucile Packard Children's Hospital Stanford, NewYork-Presbyterian/Columbia, Children's Hospital of Philadelphia, and the University of Texas Medical Branch. As of Q1 2026, six sites were activated, three patients had been treated, and 95% of commercially insured U.S. lives were covered under payer policies. Revenue is recognized on a per-treatment basis, and the company benefited from a permanent CMS J-code established effective January 1, 2026.

Abeona's development pipeline is anchored by ABO-701 (PSMA-SIR-T), an engineered T-cell therapy for advanced prostate cancer licensed from Angeles Therapeutics (Reverence Enterprises) in March 2026, and ABO-503, an AAV gene therapy for X-linked retinoschisis selected for the FDA Rare Disease Endpoint Advancement Pilot Program in October 2025. The company has historically supplemented product revenue with licensing and royalty streams from out-licensed assets, including tiered royalties (mid-single-digits to 8%) plus up to $30 million in commercial milestones from Ultragenyx for ABO-102 (Sanfilippo syndrome type A), and earned a one-time $155 million gain in 2025 from the sale of the Rare Pediatric Disease Priority Review Voucher granted alongside ZEVASKYN's approval.

Short descriptiontext

Abeona Therapeutics is a commercial-stage biopharmaceutical company developing cell and gene therapies, with its FDA-approved ZEVASKYN (prademagene zamikeracel) being the first and only gene therapy for recessive dystrophic epidermolysis bullosa (RDEB) wounds, priced at $6.2M per two-cycle treatment.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersCleveland, United States
HQ citystring
Cleveland
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell and gene therapies, autologous gene therapy, rare disease treatments, biopharmaceutical manufacturing, engineered T-cell therapy
Industry2 codes
PRIMARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAAKAC
Cell Therapy Manufacturing Services (GMP, autologous/allogeneic)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biopharmaceutical Gene Therapy
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1ZEVASKYN Product Sales
TypeOne Time License
Description

Revenue generated from sales of ZEVASKYN gene therapy product to qualified treatment centers. ZEVASKYN is sold as a single treatment application for RDEB wounds.

investors.abeonatherapeutics.com
2Licensing and Milestone Revenue
TypeLicensing Royalties
Description

Revenue from out-licensing technology including AAV capsids to third parties, with potential event-based milestones up to $24M and sales-based milestones up to $45M, plus royalties.

investors.abeonatherapeutics.com
3Ultragenyx Royalty Stream
TypeLicensing Royalties
Description

Tiered royalties from mid-single-digits to 8% on net sales of ABO-102 (Sanfilippo syndrome type A), plus up to $30M in commercial milestone payments.

investors.abeonatherapeutics.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
Pricing details1 tier
1ZEVASKYN gene therapy treatment - $6.2 million for two treatment cycles
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

ZEVASKYN (prademagene zamikeracel) is priced at $6.2 million for two treatment cycles for recessive dystrophic epidermolysis bullosa. The therapy offers a new option for patients with a severe skin condition caused by a defect in the COL7A1 gene.

pharmacytimes.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1ZEVASKYN (prademagene zamikeracel)
Description

FDA-approved gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), the first and only autologous cell-based gene therapy for this condition.

investors.abeonatherapeutics.com
+3 more records
Core offering1 text field

Abeona Therapeutics is a commercial-stage biopharmaceutical company that develops and commercializes cell and gene therapies. Its flagship product, ZEVASKYN (prademagene zamikeracel), is the first and only FDA-approved autologous cell-based gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB). The company also maintains a development pipeline including PSMA-SIR-T (ABO-701) for prostate cancer and ABO-503 for X-linked retinoschisis, and operates a fully integrated cGMP manufacturing facility in Cleveland, Ohio.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • ZEVASKYN received FDA approval on April 28, 2025 as the first and only autologous cell-based gene therapy for RDEB wounds
+3 more records
Product overview1 text field

Abeona Therapeutics is a commercial-stage biopharmaceutical company with ZEVASKYN (prademagene zamikeracel) as its FDA-approved flagship product—the first and only autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB). The company operates a fully integrated cGMP manufacturing facility in Cleveland, Ohio. Its development pipeline includes ABO-701 (PSMA-SIR-T), an engineered T-cell therapy for prostate cancer, and ABO-503 for X-linked retinoschisis.

Product and service3 records
1ZEVASKYN (prademagene zamikeracel)
CategoryCell and Gene Therapy
Description

FDA-approved autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). Uses gene-modified cellular sheets to promote wound healing with a single application. Administered through Qualified Treatment Centers.

2ABO-701 (PSMA-SIR-T)
CategoryEngineered T-Cell Therapy
Description

Engineered T-cell therapy targeting Prostate-Specific Membrane Antigen (PSMA) for advanced prostate cancer. Features Synthetic Immune Receptor (SIR-T) technology designed to overcome limitations of CAR and TCR approaches in solid tumors.

3ABO-503
CategoryGene Therapy
Description

Gene therapy for X-linked retinoschisis (XLRS), a genetic eye disorder causing retinal damage and vision loss. Selected for FDA's Rare Disease Endpoint Advancement (RDEA) Pilot Program.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Reverence Enterprises, LLC (Angeles Therapeutics subsidiary)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-18
Description

License and Joint Development Agreement for PSMA-SIR-T (ABO-701) engineered T-cell therapy targeting PSMA-positive prostate cancer. Abeona obtained exclusive license to develop and commercialize the therapy. Abeona agreed to file an IND and conduct a Phase 1 Study. Total potential deal value includes $7M upfront and up to $1M in milestone payments.

investors.abeonatherapeutics.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-05-16
Description

Exclusive license agreement for AAV gene therapy ABO-102 (Sanfilippo syndrome type A/MPS IIIA). Ultragenyx assumed responsibility for development, manufacturing, and commercialization worldwide. Abeona eligible for tiered royalties from mid-single-digits to 8% on net sales plus up to $30M commercial milestones.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2020-08-01
Description

Sublicense agreements for CLN1 disease gene therapy (ABO-202/TSHA-118) and Rett Syndrome gene therapy. Taysha received worldwide exclusive rights. Agreements were jointly terminated on February 25, 2026.

4The Board of Trustees of Leland Stanford Junior University
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2016-01-01
Description

Licensing agreements for EB-101 (LZRSE-Col7A1 Engineered Autologous Epidermal Sheets) and EB-201 (AAV DJ COL7A1) for RDEB gene therapy. Abeona pays upfront licensing fees, annual maintenance fees, milestone payments, and low single-digit royalties on net sales.

investors.abeonatherapeutics.com
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2016-01-01
Description

Licensed international patent family covering novel AAV capsids (AIM capsids) for gene therapy delivery. Also licensed rights to CLN1 disease (infantile Batten disease) and Rett Syndrome programs. Abeona sublicensed some rights to Taysha Gene Therapies.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Commercial-stage gene therapy company with Vyjuvek, the first FDA-approved topical gene therapy for dystrophic epidermolysis bullosa (DEB) — the closest direct competitor to Abeona's ZEVASKYN in the same DEB indication, with a similar ultra-rare disease, single-application treatment model.

TypeDirect peer
Description

Commercial-stage gene therapy company with Elevidys for Duchenne muscular dystrophy and a pipeline of AAV-based therapies for rare neuromuscular diseases — closely comparable business model of approved genetic medicines targeting rare diseases with high-price, single-application treatment economics.

TypeBroad incumbent
Description

Established rare disease biopharma with Roctavian (AAV gene therapy for hemophilia A) and a broader portfolio of rare genetic disease therapeutics — comparable in the rare-disease gene therapy commercial model but with substantially greater scale and a more diversified portfolio.

TypeDirect peer
Description

Clinical-stage gene therapy company developing AAV-based therapies for rare diseases including hemophilia B and Huntington's disease — a directly comparable AAV gene therapy peer in the rare disease space with similar technology foundation and pre-commercial/early-commercial stage.

5bluebird bio
TypeDirect peer
Description

Gene therapy company commercializing Zynteglo for beta-thalassemia and Skysona for cerebral adrenoleukodystrophy — comparable as a developer of approved, ultra-rare disease gene therapies with similar pricing and treatment-center delivery model, though currently undergoing strategic restructuring.

TypeDirect peer
Description

Clinical-stage genetic medicines company developing AAV gene therapies for Duchenne muscular dystrophy and other rare neuromuscular diseases — comparable as a small-cap rare-disease gene therapy developer with similar technology platform and pipeline-stage economics.

TypeDirect peer
Description

Clinical-stage gene therapy company focused on rare monogenic diseases of the central nervous system — a directly comparable rare-disease AAV gene therapy peer and former sublicensee of Abeona's CLN1 and Rett Syndrome programs (jointly terminated Feb 2026).

TypeEmerging player
Description

Clinical-stage gene therapy and genome editing company developing AAV and zinc finger nuclease-based therapies for rare genetic diseases and neurology — comparable as a smaller rare-disease gene therapy peer with platform-level technology overlap, though Sangamo is broader in editing modalities.

TypeBroad incumbent
Description

Commercial-stage rare disease biopharma with multiple approved products across genetic diseases — directly comparable as Abeona's exclusive licensee for ABO-102 (Sanfilippo A) and operates in the same ultra-rare genetic disease commercial space with substantially greater scale.

TypeBroad incumbent
Description

Large-cap biopharma with Casgevy, the first FDA-approved CRISPR/Cas9 gene-edited cell therapy for sickle cell disease and beta-thalassemia — comparable as a leader in approved genetic medicines targeting rare diseases, with substantially greater scale and a broader commercial and pipeline portfolio.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds14 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors19 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Abeona Therapeutics

Biopharmaceutical Gene Therapyabeonatherapeutics.com

Abeona Therapeutics is a commercial-stage biopharmaceutical company developing cell and gene therapies, with its FDA-approved ZEVASKYN (prademagene zamikeracel) being the first and only gene therapy for recessive dystrophic epidermolysis bullosa (RDEB) wounds, priced at $6.2M per two-cycle treatment.

What Abeona Therapeutics does

Abeona Therapeutics Inc. (NASDAQ: ABEO) is a commercial-stage biopharmaceutical company headquartered in Cleveland, Ohio that develops cell and gene therapies for serious rare diseases. Its lead and only commercial product is ZEVASKYN (prademagene zamikeracel), which received FDA approval on April 28, 2025 as the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB), a severe genetic skin disease caused by a defect in the COL7A1 gene. The therapy uses gene-modified cellular sheets applied to chronic wounds and is priced at $6.2 million for two treatment cycles.

ZEVASKYN is manufactured at Abeona's fully integrated cGMP cell and gene therapy facility in Cleveland and administered exclusively through a Qualified Treatment Center network that includes Lucile Packard Children's Hospital Stanford, NewYork-Presbyterian/Columbia, Children's Hospital of Philadelphia, and the University of Texas Medical Branch. As of Q1 2026, six sites were activated, three patients had been treated, and 95% of commercially insured U.S. lives were covered under payer policies. Revenue is recognized on a per-treatment basis, and the company benefited from a permanent CMS J-code established effective January 1, 2026.

Abeona's development pipeline is anchored by ABO-701 (PSMA-SIR-T), an engineered T-cell therapy for advanced prostate cancer licensed from Angeles Therapeutics (Reverence Enterprises) in March 2026, and ABO-503, an AAV gene therapy for X-linked retinoschisis selected for the FDA Rare Disease Endpoint Advancement Pilot Program in October 2025. The company has historically supplemented product revenue with licensing and royalty streams from out-licensed assets, including tiered royalties (mid-single-digits to 8%) plus up to $30 million in commercial milestones from Ultragenyx for ABO-102 (Sanfilippo syndrome type A), and earned a one-time $155 million gain in 2025 from the sale of the Rare Pediatric Disease Priority Review Voucher granted alongside ZEVASKYN's approval.

Abeona Therapeutics firmographics

Firmographics
Name
Abeona Therapeutics
Legal name
Abeona Therapeutics Inc.
Website
https://abeonatherapeutics.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
101–250 employees
Short description
Abeona Therapeutics is a commercial-stage biopharmaceutical company developing cell and gene therapies, with its FDA-approved ZEVASKYN (prademagene zamikeracel) being the first and only gene therapy for recessive dystrophic epidermolysis bullosa (RDEB) wounds, priced at $6.2M per two-cycle treatment.
Ownership category
akta.pro rank

Abeona Therapeutics industry classification

Industry
Product category
Biopharmaceutical Gene Therapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAAKAC
Cell Therapy Manufacturing Services (GMP, autologous/allogeneic)

Keywords

  • Cell and gene therapies
  • Autologous gene therapy
  • Rare disease treatments
  • Biopharmaceutical manufacturing
  • Engineered T-cell therapy

Where Abeona Therapeutics is headquartered

Location

Headquarters

HQ city
Cleveland
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Abeona Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. ZEVASKYN Product Sales: Revenue generated from sales of ZEVASKYN gene therapy product to qualified treatment centers. ZEVASKYN is sold as a single treatment application for RDEB wounds.
  2. Licensing and Milestone Revenue: Revenue from out-licensing technology including AAV capsids to third parties, with potential event-based milestones up to $24M and sales-based milestones up to $45M, plus royalties.
  3. Ultragenyx Royalty Stream: Tiered royalties from mid-single-digits to 8% on net sales of ABO-102 (Sanfilippo syndrome type A), plus up to $30M in commercial milestone payments.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goZEVASKYN gene therapy treatment - $6.2 million for two treatment cycles

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Abeona Therapeutics product offering

Product offering

Core offering

Abeona Therapeutics is a commercial-stage biopharmaceutical company that develops and commercializes cell and gene therapies. Its flagship product, ZEVASKYN (prademagene zamikeracel), is the first and only FDA-approved autologous cell-based gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB). The company also maintains a development pipeline including PSMA-SIR-T (ABO-701) for prostate cancer and ABO-503 for X-linked retinoschisis, and operates a fully integrated cGMP manufacturing facility in Cleveland, Ohio.

Product overview

Abeona Therapeutics is a commercial-stage biopharmaceutical company with ZEVASKYN (prademagene zamikeracel) as its FDA-approved flagship product—the first and only autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB). The company operates a fully integrated cGMP manufacturing facility in Cleveland, Ohio. Its development pipeline includes ABO-701 (PSMA-SIR-T), an engineered T-cell therapy for prostate cancer, and ABO-503 for X-linked retinoschisis.

Differentiator

Problem solved

Functional benefit

Brands

  • ZEVASKYN (prademagene zamikeracel): FDA-approved gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), the first and only autologous cell-based gene therapy for this condition.
  • Abeona Assist
  • PSMA-SIR-T (ABO-701)
  • AIM capsids

Products and services

  • ZEVASKYN (prademagene zamikeracel) FDA-approved autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). Uses gene-modified cellular sheets to promote wound healing with a single application. Administered through Qualified Treatment Centers.
  • ABO-701 (PSMA-SIR-T) Engineered T-cell therapy targeting Prostate-Specific Membrane Antigen (PSMA) for advanced prostate cancer. Features Synthetic Immune Receptor (SIR-T) technology designed to overcome limitations of CAR and TCR approaches in solid tumors.
  • ABO-503 Gene therapy for X-linked retinoschisis (XLRS), a genetic eye disorder causing retinal damage and vision loss. Selected for FDA's Rare Disease Endpoint Advancement (RDEA) Pilot Program.

Quantifiable outcome

  • ZEVASKYN received FDA approval on April 28, 2025 as the first and only autologous cell-based gene therapy for RDEB wounds
  • +3 more outcomes

Companies that use Abeona Therapeutics

Customer profile

Named customers3 records

Segments1 record

Ideal customer profiles2 records

Abeona Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Abeona Therapeutics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Reverence Enterprises, LLC (Angeles Therapeutics subsidiary)coreStrategic or Co-development Partner · 18 March 2026License and Joint Development Agreement for PSMA-SIR-T (ABO-701) engineered T-cell therapy targeting PSMA-positive prostate cancer. Abeona obtained exclusive license to develop and commercialize the therapy. Abeona agreed to file an IND and conduct a Phase 1 Study. Total potential deal value includes $7M upfront and up to $1M in milestone payments.
  • Ultragenyx Pharmaceutical Inc.coreStrategic or Co-development Partner · 16 May 2022Exclusive license agreement for AAV gene therapy ABO-102 (Sanfilippo syndrome type A/MPS IIIA). Ultragenyx assumed responsibility for development, manufacturing, and commercialization worldwide. Abeona eligible for tiered royalties from mid-single-digits to 8% on net sales plus up to $30M commercial milestones.
  • Taysha Gene TherapiesminorStrategic or Co-development Partner · 1 August 2020Sublicense agreements for CLN1 disease gene therapy (ABO-202/TSHA-118) and Rett Syndrome gene therapy. Taysha received worldwide exclusive rights. Agreements were jointly terminated on February 25, 2026.
  • The Board of Trustees of Leland Stanford Junior UniversitycoreTechnology or Integration · 1 January 2016Licensing agreements for EB-101 (LZRSE-Col7A1 Engineered Autologous Epidermal Sheets) and EB-201 (AAV DJ COL7A1) for RDEB gene therapy. Abeona pays upfront licensing fees, annual maintenance fees, milestone payments, and low single-digit royalties on net sales.
  • University of North Carolina at Chapel HillcoreTechnology or Integration · 1 January 2016Licensed international patent family covering novel AAV capsids (AIM capsids) for gene therapy delivery. Also licensed rights to CLN1 disease (infantile Batten disease) and Rett Syndrome programs. Abeona sublicensed some rights to Taysha Gene Therapies.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Abeona Therapeutics competitors and assessment

Company assessment

Direct peers

  • Krystal Biotech: Commercial-stage gene therapy company with Vyjuvek, the first FDA-approved topical gene therapy for dystrophic epidermolysis bullosa (DEB) — the closest direct competitor to Abeona's ZEVASKYN in the same DEB indication, with a similar ultra-rare disease, single-application treatment model.
  • Sarepta Therapeutics: Commercial-stage gene therapy company with Elevidys for Duchenne muscular dystrophy and a pipeline of AAV-based therapies for rare neuromuscular diseases — closely comparable business model of approved genetic medicines targeting rare diseases with high-price, single-application treatment economics.
  • uniQure: Clinical-stage gene therapy company developing AAV-based therapies for rare diseases including hemophilia B and Huntington's disease — a directly comparable AAV gene therapy peer in the rare disease space with similar technology foundation and pre-commercial/early-commercial stage.
  • bluebird bio: Gene therapy company commercializing Zynteglo for beta-thalassemia and Skysona for cerebral adrenoleukodystrophy — comparable as a developer of approved, ultra-rare disease gene therapies with similar pricing and treatment-center delivery model, though currently undergoing strategic restructuring.
  • Solid Biosciences: Clinical-stage genetic medicines company developing AAV gene therapies for Duchenne muscular dystrophy and other rare neuromuscular diseases — comparable as a small-cap rare-disease gene therapy developer with similar technology platform and pipeline-stage economics.
  • Taysha Gene Therapies: Clinical-stage gene therapy company focused on rare monogenic diseases of the central nervous system — a directly comparable rare-disease AAV gene therapy peer and former sublicensee of Abeona's CLN1 and Rett Syndrome programs (jointly terminated Feb 2026).

Broad incumbents

  • BioMarin Pharmaceutical: Established rare disease biopharma with Roctavian (AAV gene therapy for hemophilia A) and a broader portfolio of rare genetic disease therapeutics — comparable in the rare-disease gene therapy commercial model but with substantially greater scale and a more diversified portfolio.
  • Ultragenyx Pharmaceutical: Commercial-stage rare disease biopharma with multiple approved products across genetic diseases — directly comparable as Abeona's exclusive licensee for ABO-102 (Sanfilippo A) and operates in the same ultra-rare genetic disease commercial space with substantially greater scale.
  • Vertex Pharmaceuticals: Large-cap biopharma with Casgevy, the first FDA-approved CRISPR/Cas9 gene-edited cell therapy for sickle cell disease and beta-thalassemia — comparable as a leader in approved genetic medicines targeting rare diseases, with substantially greater scale and a broader commercial and pipeline portfolio.

Emerging players

  • Sangamo Therapeutics: Clinical-stage gene therapy and genome editing company developing AAV and zinc finger nuclease-based therapies for rare genetic diseases and neurology — comparable as a smaller rare-disease gene therapy peer with platform-level technology overlap, though Sangamo is broader in editing modalities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Abeona Therapeutics social profiles

Digital presence

Abeona Therapeutics compliance and trust

Trust signal

Compliance2 records

Abeona Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Abeona Therapeutics leadership team

Management profile

Number of profiles

Profiles8 records

Abeona Therapeutics funding detail

Funding detail

Funding overview

Funding rounds14 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Abeona Therapeutics M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Abeona Therapeutics

What does Abeona Therapeutics do?

Abeona Therapeutics is a commercial-stage biopharmaceutical company that develops and commercializes cell and gene therapies. Its flagship product, ZEVASKYN (prademagene zamikeracel), is the first and only FDA-approved autologous cell-based gene therapy for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB). The company also maintains a development pipeline including PSMA-SIR-T (ABO-701) for prostate cancer and ABO-503 for X-linked retinoschisis, and operates a fully integrated cGMP manufacturing facility in Cleveland, Ohio.

Is Abeona Therapeutics a public or private company?

Abeona Therapeutics is a public company. It is classified as public and is currently operating.

When was Abeona Therapeutics founded?

Abeona Therapeutics was founded in 2015. It employs 101 to 250 people.

Where is Abeona Therapeutics based?

Abeona Therapeutics is headquartered in Cleveland, United States, in the North America region.

How does Abeona Therapeutics make money?

Three revenue lines are on record. ZEVASKYN Product Sales are the primary driver. The others are licensing and Milestone Revenue and ultragenyx Royalty Stream.

Who are Abeona Therapeutics's main competitors?

Direct peers on record are Krystal Biotech, Sarepta Therapeutics, uniQure, bluebird bio, Solid Biosciences and Taysha Gene Therapies. Broad incumbents are BioMarin Pharmaceutical, Ultragenyx Pharmaceutical and Vertex Pharmaceuticals. Sangamo Therapeutics is listed as an emerging player.

Does Abeona Therapeutics have an API?

No public API is recorded for Abeona Therapeutics.

What industry is Abeona Therapeutics in?

Abeona Therapeutics's product category is Biopharmaceutical Gene Therapy. Its primary akta.pro industry code is HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics, with a secondary code of HLAAAKAC, Cell Therapy Manufacturing Services (GMP, autologous/allogeneic). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaAbeona Therapeutics: My 'Buy The Dip' Call Backfired On Q3 Earnings: I'm Downgrading To HoldAn analyst who recommended Abeona Therapeutics in August now downgrades to Hold after the stock fell over 55% in three months. The stock trades at $2.73, down from the analyst's buy recommendation.TradingViewABEO: ZEVASKYN launch ramp leads, with ABO-801 and partnered-program catalysts aheadABEO's ZEVASKYN launch ramp leads, with all eight QTCs targeted to treat patients by mid-2027 and cadence expected to rise. ABO-801's proposed Phase III design will be discussed with the FDA in H1 2027, alongside manufacturing updates and partnered-program catalysts.Investing.comAbeona at Jefferies Global Healthcare Conference: launch tests and pipeline buildAbeona Therapeutics launched ZEVASKYN for RDEB at the Jefferies Global Healthcare Conference, with 15 patients treated across eight centers. The company cited manufacturing issues and coordination barriers, targeting double-digit quarterly pace by mid-2027. It also highlighted the ABO-801 program for eosinophilic esophagitis.YahooAbeona Therapeutics (ABEO) Stock Sees Fair Value Falls As Zevaskyn Ramp Concerns GrowAnalysts cut Abeona Therapeutics' fair value estimate from about $20.64 to $15.56, reflecting concerns over Zevaskyn's slower ramp and dilution. H.C. Wainwright and Roth Capital both lowered price targets, with Roth cutting to $7.50 from $17. The company's revenue growth assumption fell to 87.52%.American Banking and Market NewsAbeona Therapeutics (NASDAQ:ABEO) Stock Bumped Up to Hold by Wall Street ZenWall Street Zen upgraded Abeona Therapeutics from a sell to a hold rating. The stock opened at $2.42, with a consensus rating of Moderate Buy and an average price target of $21.00. Insiders sold 55,428 shares over the last 90 days.TradingViewHC Wainwright & Co. maintains Abeona Therapeutics at Buy, lowers price target to $18 from $20HC Wainwright & Co. maintained Abeona Therapeutics at Buy and lowered its price target to $18 from $20, a 10% decrease. The target implies an upside of 682.6% from the Nov 11 close of $2.30.GlobeNewswireAbeona Therapeutics® Announces Participation in Upcoming Investor ConferencesAbeona Therapeutics announced its management team will participate in the Stifel Healthcare Conference on November 11 and the Jefferies Global Healthcare Conference on November 18, 2026. Live webcasts and replays will be available on the company's investor website.Stock TitanAbeona to Participate in Two November Investor ConferencesAbeona Therapeutics management will participate in the Stifel and Jefferies healthcare investor conferences in November 2026. The Stifel fireside chat is on November 11 at 8:40 AM ET, and the Jefferies presentation is on November 18 at 10:30 AM GMT. Live webcasts will be available on the company's investor page.The Motley FoolAbeona Therapeutics (ABEO) Q3 2026 Earnings Call TranscriptAbeona Therapeutics reported Q3 2026 net revenue of $13.5 million, up 18% from the prior quarter, and a net loss of $4.8 million. The company announced the acquisition of ABO-801, a Phase III-ready EoE drug, and plans to start its Phase III trial in mid-2027. A $30 million private placement was announced to fund pipeline development and ZEVASKYN commercialization.MarketScreenerAbeona Therapeutics Inc. Acquires Phase 3-Ready ABO-801 and Announces Private PlacementAbeona Therapeutics acquired ABO-801, a Phase 3-ready oral disintegrating tablet for eosinophilic esophagitis, from Ellodi Pharmaceuticals. The deal includes a $30 million private placement and no upfront cash, with Ellodi eligible for up to $60 million in milestone payments. Abeona plans to start a Phase 3 study in mid-2027, expecting topline results by end of 2028.